Suppr超能文献

口服避孕药使用期间纤溶活性增加被纤溶增强的不依赖于因子XI的下调所抵消:两种低剂量口服避孕药的随机交叉研究。

Increased fibrinolytic activity during use of oral contraceptives is counteracted by an enhanced factor XI-independent down regulation of fibrinolysis: a randomized cross-over study of two low-dose oral contraceptives.

作者信息

Meijers J C, Middeldorp S, Tekelenburg W, van den Ende A E, Tans G, Prins M H, Rosing J, Büller H R, Bouma B N

机构信息

Department of Haematology, University Medical Center Utrecht, The Netherlands.

出版信息

Thromb Haemost. 2000 Jul;84(1):9-14.

Abstract

The effect of oral contraceptives (OC) on fibrinolytic parameters was investigated in a cycle-controlled cross-over study in which 28 non-OC using women were randomly prescribed either a representative of the so-called second (30 microg ethinylestradiol, 150 microg levonorgestrel) or third generation OC (30 microg ethinylestradiol, 150 microg desogestrel) and who switched OC after a two month wash out period. During the use of OC, the levels of tissue-type plasminogen activator (tPA) activity, plasminogen, plasmin-alpha2-antiplasmin complexes and D-dimer significantly increased (by 30 to 80%), while the levels of plasminogen activator inhibitor- (PAI-1) antigen, PAI-1 activity and tPA antigen significantly decreased (25 to 50%), suggesting an increase in endogenous fibrinolytic activity. These OC-induced changes were not different between the two contraceptive pills. TAFI (thrombin-activatable fibrinolysis inhibitor) levels increased on levonorgestrel, and even further increased on desogestrel. A clot lysis assay that probes both fibrinolytic activity and the efficacy of the coagulation system to generate thrombin necessary to down regulate fibrinolysis via TAFI showed no change of the clot lysis time during OC use. This finding suggests that the OC-induced increase in endogenous fibrinolytic activity is counteracted by an increased capacity of the coagulation system to down regulate fibrinolysis via TAFI. Indeed we observed that during OC use there was a significant increase of F1+2 generation during clot formation. When these assays were performed in the presence of an antibody against factor XI, we observed that the clot lysis time was significantly increased during OC use and that the increase in F1+2 generation during OC therapy was due to a factor XI-independent process, which was significantly higher on desogestrel than on levonorgestrel. These data indicate that the OC-induced inhibition of endogenous fibrinolysis takes place in a factor XI-independent way and is more pronounced on desogestrel than on levonorgestrel-containing OC.

摘要

在一项周期对照交叉研究中,对口服避孕药(OC)对纤维蛋白溶解参数的影响进行了调查。该研究中,28名未使用OC的女性被随机给予所谓第二代OC(30微克炔雌醇,150微克左炔诺孕酮)或第三代OC(30微克炔雌醇,150微克去氧孕烯)的一种,并在两个月的洗脱期后更换OC。在使用OC期间,组织型纤溶酶原激活物(tPA)活性、纤溶酶原、纤溶酶-α2-抗纤溶酶复合物和D-二聚体水平显著升高(升高30%至80%),而纤溶酶原激活物抑制剂-1(PAI-1)抗原、PAI-1活性和tPA抗原水平显著降低(降低25%至50%),提示内源性纤维蛋白溶解活性增加。两种避孕药之间这些由OC引起的变化并无差异。左炔诺孕酮使凝血酶激活的纤维蛋白溶解抑制剂(TAFI)水平升高,而去氧孕烯使其进一步升高。一项同时检测纤维蛋白溶解活性和凝血系统通过TAFI下调纤维蛋白溶解所需凝血酶生成能力的凝块溶解试验显示,在使用OC期间凝块溶解时间无变化。这一发现表明,OC引起的内源性纤维蛋白溶解活性增加被凝血系统通过TAFI下调纤维蛋白溶解能力的增强所抵消。实际上,我们观察到在使用OC期间,凝块形成过程中F1+2生成显著增加。当在存在抗因子XI抗体的情况下进行这些试验时,我们观察到在使用OC期间凝块溶解时间显著延长,且OC治疗期间F1+2生成增加是由于一个不依赖因子XI的过程,该过程在去氧孕烯组比左炔诺孕酮组显著更高。这些数据表明,OC引起的内源性纤维蛋白溶解抑制以不依赖因子XI的方式发生,且在含去氧孕烯的OC上比含左炔诺孕酮的OC更明显。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验